8-K
filed October 31, 2023, 7:59 PM ET
ticker RNTX
CIK 0001420565
M&A
confidence high
sentiment neutral
materiality 0.90
Rein Therapeutics, Inc. (RNTX): auditor change — Aileron acquires Lung Therapeutics in stock deal, raises $18M via PIPE, appoints new COO
Rein Therapeutics, Inc.
- Acquired Lung Therapeutics for 344,566 shares of common stock and 20,140 shares of Series X Preferred; post-merger shares outstanding ~4.89M.
- Raised ~$18M in private placement with Bios Partners, Nantahala Capital, and others; includes Series X Preferred and warrants exercisable at $4.89/share.
- Dismissed PricewaterhouseCoopers as auditor effective upon merger close; PwC had included a going concern paragraph in prior reports.
- Appointed Brian Windsor, former Lung CEO, as President and COO; elected William Fairey and Alan Musso to the board.
- Jeffrey Bailey, Jodie Morrison, and William McKee resigned from the board; Josef von Rickenbach named chairman.
Key facts
Extracted from this filing and checked against the source text.
Auditor Changes
SEC 8-K Item 4.01/4.02
confidence 0.9
Rein Therapeutics, Inc. dismissed PricewaterhouseCoopers LLP as its auditor.
- Action
- dismissal
- Auditor
- PricewaterhouseCoopers LLP
Exact text from the filing
Aileron dismissed its independent registered public accounting firm, PricewaterhouseCoopers LLP ("PwC"), effective immediately upon the closing of the Merger.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brian Windsor was appointed as President and Chief Operating Officer at Rein Therapeutics, Inc..
- Action
- appointed
- Role
- President and Chief Operating Officer
Exact text from the filing
On October 30, 2023, the Board approved the appointment of Brian Windsor, Ph.D., age 57, to President and Chief Operating Officer of Aileron, effective as of the consummation of the Merger.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Josef H. von Rickenbach was appointed as Chairman of the Board at Rein Therapeutics, Inc..
- Action
- appointed
- Role
- Chairman of the Board
Exact text from the filing
Following Mr. Bailey's resignation, Josef H. von Rickenbach will serve as the Chairman of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jodie P. Morrison resigned as Director at Rein Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
William T. McKee resigned as Director at Rein Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeffrey A. Bailey resigned as Chairman of the Board at Rein Therapeutics, Inc..
- Action
- resigned
- Role
- Chairman of the Board
Exact text from the filing
On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Rein Therapeutics, Inc.: Filed Certificate of Designation for Series X Non-Voting Convertible Preferred Stock (effective 2023-10-31).
- Change
- charter amendment
- Effective
- 2023-10-31
Exact text from the filing
On October 31, 2023, Aileron filed a Certificate of Designation of Preferences, Rights and Limitations of the Series X Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Merger and the Financing referenced in Item 1.01 above.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Rein Therapeutics, Inc. completed an acquisition involving Lung Therapeutics, Inc. (closed 2023-10-31).
- Action
- acquisition
- Counterparty
- Lung Therapeutics, Inc.
- Closing
- 2023-10-31
Exact text from the filing
On October 31, 2023, Aileron completed its acquisition of Lung.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Rein Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $18.0 million (effective 2023-10-31).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- approximately $18.0 million
- Effective
- 2023-10-31
Exact text from the filing
Immediately following the closing of the Merger, on October 31, 2023, Aileron entered into a Stock and Warrant Purchase Agreement (the “ Purchase Agreement ”) with a group of accredited investors (the “ Investors ”) led by Bios Partners, the majority shareholder of Lung prior to the closing of the Merger, and including Nantahala Capital, as well as additional undisclosed investors.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Rein Therapeutics, Inc. entered into Merger Agreement with Lung.
- Action
- entry
- Agreement
- merger
- Counterparty
- Lung
Exact text from the filing
Pursuant to the Merger Agreement, Aileron has agreed to hold a stockholders’ meeting no later than 120 days after the date on which the closing of the Merger occurs
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.